This site is intended for US Healthcare Professionals

Type Size: A A A
For US Healthcare Professionals Only  |  For Non-US Residents


Video Library

Watch videos of Editorial Board members discussing CTEPH pathology, symptomology, diagnosis, and more.

Case Studies

Review CTEPH case studies focusing on CTEPH symptom presentation and optimal treatment in various diagnostic contexts.

This site is dedicated to raising awareness about CTEPH and providing you with a resource to better understand:

Chronic Thromboembolic Pulmonary Hypertension, or CTEPH, is a rare, life-threatening medical condition whose most commonly reported symptoms include exercise intolerance, fatigue, and dyspnea. Subsequently, patients may report chest discomfort, syncope, hemoptysis, light-headedness, or peripheral leg edema.1

The symptoms experienced by CTEPH patients are similar to those of other more common diseases, like asthma and chronic obstructive pulmonary disease, and to those of other types of pulmonary hypertension (PH). In part because these symptoms are nonspecific, CTEPH is underdiagnosed, and it is often misdiagnosed as another disease.1,2

But CTEPH is unique among the five groups of pulmonary hypertension (PH) in that it is potentially curable only with pulmonary thromboendarterectomyII (PTE) surgery, which is the treatment of choice for patients who are surgical candidates.1 is supported by Bayer HealthCare. Bayer is committed to advancing CTEPH best practices,3 including working to help educate the community that:

  • All persons in whom PH is suspected should receive a ventilation/perfusion scan to screen for CTEPH.3
  • All persons diagnosed with CTEPH should be assessed for potentially curative PTE surgery by an expert center.3

View the Bayer CTEPH Mission

*Based on a study with 223 patients in which 3.8% were diagnosed with CTEPH within 2 years of their first episode of pulmonary embolism with or without prior deep-vein thrombosis (95% CI, 1.1 to 6.5). CTEPH did not develop after two years in any of the 132 remaining patients with more than 2 years of follow up.

Wilkens H et al. Int J Cardiol. 2011;154S:S54-S60.

Pengo V et al. N Engl J Med. 2004;350(22):2257-2264.

§Tapson VF and Humbert M. Proc Am Thorac Soc. 2006;3(7):564-567.

IIAlso called pulmonary endarterectomy or PEA.